Hemocoagulation and Lipoperoxidation in Women Using Combined Oral Contraceptives, Correction by Antioxidants

• Status: Unknown status
• Trial end date: 2015-10-01
• Target enrollment: 0
• Participant gender: Female

Summary

We investigate parameters of hemocoagulation and lipoperoxidation in women using combined oral contraceptives with antiandrogenic activity (containing drospirenone with 20 or 30 mcg ethinylestradiol; or cyproterone acetate); correction of these changes by antioxidants

• Phase: Phase 4
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Tyumen State Medical Academy
• Treatments: Antioxidants; Contraceptive Agents; Contraceptives, Oral; Contraceptives, Oral, Combined; Cyproterone; Cyproterone Acetate; Cyproterone acetate, ethinyl estradiol drug combination; Drospirenone; Drospirenone and ethinyl estradiol combination; Ethinyl Estradiol

Criteria

Inclusion Criteria:

• Women aged 18-35 years

• Absence of contraindications for COC use

• Informed voluntary consent for examination

Exclusion Criteria:

• Age younger than 18 and older than 35 years

• Refusal or failure to comply with the study protocol

• Drug or alcohol dependence

• Psychiatric diseases

• Severe somatic and allergic diseases

• Pregnancy

• Malignancies

• Taking drugs that affect haemostasis, including hormonal contraceptives during 6 months before study beginning

• Cases of thrombosis among first-line relatives in family history

• Contraindications to the COC use under Eligibility Criteria of hormonal contraception (WHO, 2012)